IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth

In this study, we identified the regulatory targets of IGF2BP3 in breast cancer MDA-MB-231 cells using RNA immunoprecipitation sequencing (RIP-seq) and high-throughput RNA-sequencing (RNA-seq). We discovered that these targets were enriched in the inflammatory response, endoplasmic reticulum stress, cell cycle, and cancer-related pathways, providing a new perspective for better understanding the functional mechanisms of IGF2BP3. Moreover, we identified that the epidermal growth factor receptor (EGFR), a downstream target, is regulated by IGF2BP3. IGF2BP3 binds to and protects EGFR mRNA from degradation and facilitates cell proliferation via the EGFR/AKT pathway in MDA-MB-231 cells. In addition, IGF2BP3 expression was robust and could not be altered by stimulation with EGF and anti-EGFR siRNA or EGFR signaling pathway inhibitors (gefitinib, LY294002 and SL-327). These results demonstrate that IGF2BP3, as a stubborn oncogene, promotes triple-negative breast cancer MDA-MB-231 cell proliferation by strengthening the role of the EGFR-AKT axis.PMID:37474008 | DOI:10.1016/j.bbamcr.2023.119542

Source: Biochimica et Biophysica Acta - July 20, 2023 Category: Biochemistry Authors: Xintao Jing Cong Han Qian Li Fang Li Jinyuan Zhang Qiuyu Jiang Fei Zhao Chen Guo Jinfeng Chen Ting Jiang Xiaofei Wang Yanke Chen Chen Huang Source Type: research